In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specialises in the treatment of rare gastrointestinal cancer GIST.

The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

In a report released on January 9, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

Boston-based biotechnology firm developing therapy for treatment of gastrointestinal stromal tumors - Anadolu Ajansı ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

NEW YORK (PIX11) — A young man, homeless and disheveled, was surrounded by a joint response team made up of two NYPD officers ...